SAFETY AND EFFICACY OF AN IMPLANTABLE LEUPROLIDE DELIVERY SYSTEM IN PATIENTS WITH ADVANCED PROSTATE CANCER
- 1 September 2000
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 164 (3 Part 1) , 730-734
- https://doi.org/10.1016/s0022-5347(05)67291-6
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Long-Acting Gonadotropin-Releasing Hormone Implant to Maintain Medical Castration for Two Years in Men with Prostate CancerNew England Journal of Medicine, 1999
- Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancerUrology, 1998
- Maximal Androgen Blockade: Final Analysis of EORTC Phase III Trial 30853European Urology, 1998
- Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancerClinical Therapeutics, 1996
- A New Long Acting Formulation of the Luteinizing Hormone-Releasing Hormone Analogue, Goserelin: Results of Studies in Prostate CancerJournal of Urology, 1996
- Current status of combined androgen blockade: optimal therapy for advanced prostate cancer [published erratum appears in J Clin Endocrinol Metab 1995 Jul;80(7):2056]Journal of Clinical Endocrinology & Metabolism, 1995
- Clinical Study of Leuprolide Depot Formulation in the Treatment of Advanced Prostate CancerJournal of Urology, 1990
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984